Merck & Co. stock gains as melanoma vaccine data and drug pricing deal sharpen oncology focus

Merck & Co. stock is trading firmer as investors weigh fresh positive data from its personalized melanoma mRNA vaccine with Keytruda and the company’s role in a high-profile US drug pricing deal, while FY 2026 guidance and dividend support the valuation.

Merck & Co., Inc. (ISIN US58933Y1055) stock was quoted at 150.17 USD as of September 1, 2026 in New York trading, up 1.6 percent intraday, keeping the pharma group in focus for investors looking at large-cap oncology exposure.The finanzen.ch trading overview shows an intraday high of 151.51 USD and an opening price of 150.23 USD on the same date.

Oncology data and policy backdrop

Beyond the price move on September 1, 2026, Merck & Co. is again in the spotlight because of new data from its personalized melanoma mRNA vaccine in combination with Keytruda, its established PD-1 immunotherapy.

At the 2026 meeting of the American Society of Clinical Oncology, researchers presented five-year results from a randomized trial where high-risk melanoma patients who had undergone surgery received either Keytruda alone or Keytruda plus the personalized mRNA vaccine; adding the vaccine reduced the relative risk of recurrence or death by 49 percent and reduced the relative risk of distant metastasis or death by 59 percent compared with Keytruda alone, underscoring the potential of the combination in long-term follow-up.A detailed report in Mining Journal highlights that these five-year data support earlier interim findings.

More recently, Moderna and Merck announced that a larger Phase 3 trial also found that adding the personalized mRNA vaccine significantly reduced melanoma recurrence and distant spread compared with Keytruda alone, providing an important late-stage confirmation for the oncology strategy and reinforcing the investment case built around Keytruda and next-generation combinations.MMM Online notes that the positive melanoma results may also help improve the public perception of mRNA technology in oncology.

Guidance, dividend and consensus view

For the current fiscal year, Merck & Co. has issued FY 2026 guidance for earnings per share in a range of 2.66 to 2.76 USD, giving investors a concrete profit framework against which to judge the stock’s valuation.MarketBeat reports that equities analysts expect Merck to deliver EPS at the top end of this range at 2.76 USD for the year.

According to the same data compilation, Merck & Co. carries a consensus rating of Moderate Buy from covering analysts, with an average price target of 147.60 USD per share, which is slightly below the 150.17 USD intraday level reported on September 1, 2026 and thus indicates that the stock is trading modestly above the current consensus target.A separate MarketBeat alert also cites the same consensus rating and target price.

Income-focused investors will note that Merck has announced a quarterly dividend of 0.85 USD per share, corresponding to an annualized dividend of 3.40 USD and a yield of 2.3 percent based on recent prices, which supports the total return profile of the stock alongside oncology-driven growth ambitions.The MarketBeat overview indicates that the ex-dividend date for this payout is September 15, 2026 and that the company’s dividend payout ratio currently stands at 272.00 percent.

Drug pricing deal and DACH angle

Merck & Co. also appears in the context of a high-profile US drug pricing deal that is expanding and drawing attention to the pricing environment for large pharmaceutical groups.

In an analysis of healthcare stocks linked to this policy development, Merck & Co. is classified with a neutral stance but identified as one of the firms involved in the deal, with the note that while the agreement may reduce prices it could increase volumes, highlighting a key trade-off for long-term investors assessing revenue and margin trajectories.A CryptoRank policy and stock overview singles out Merck’s melanoma vaccine and a positive lung cancer readout for its antibody-drug conjugate sacituzumab tirumotecan as reasons why the company remains a top pick for some strategists.

For readers in the German-speaking DACH region, Merck & Co. can be accessed both on its primary listing on the New York Stock Exchange in USD and via international brokers that route orders to the US market; while Merck KGaA in Darmstadt is a separate entity traded in EUR and covered today by DACH-focused outlets, the oncology and drug pricing themes around Merck & Co. are closely watched there as a benchmark for global pharmaceutical valuations and growth narratives.Investing.com reports that Merck KGaA stock rose 1.7 percent to 141.30 EUR after an HSBC upgrade, highlighting how oncology and life-science tools valuations are a cross-border theme.

Keytruda and Gardasil as flagship products

Merck & Co.’s investment case is anchored in a portfolio of widely used medicines and vaccines, with Keytruda and Gardasil standing out as flagship products in oncology and preventive medicine.

Keytruda, a cancer immunotherapy targeting the PD-1 pathway, has become a backbone treatment in multiple tumor types, including melanoma, lung cancer and head and neck cancer, and now serves as the immunotherapy backbone in the personalized melanoma mRNA vaccine regimen that has delivered strong trial results in both five-year follow-up and the recent larger Phase 3 study.MMM Online underscores that this combination could reshape how melanoma is treated and how mRNA is perceived in oncology.

Gardasil, Merck’s human papillomavirus vaccine, remains a cornerstone of its vaccines franchise, designed to prevent HPV infections that can lead to cervical and other cancers, while Merck Animal Health adds a veterinary dimension with medicines and vaccines for livestock and companion animals.MarketBeat’s profile of Merck notes that Keytruda and Gardasil are among the company’s best-known products.

Stock price and investor takeaway

With Merck & Co. stock trading at 150.17 USD as of September 1, 2026, compared with the average analyst target of 147.60 USD, the shares are modestly above consensus while still supported by FY 2026 EPS guidance of 2.66 to 2.76 USD, a 3.40 USD annualized dividend and a pipeline that includes a personalized melanoma mRNA vaccine and antibody-drug conjugates such as sacituzumab tirumotecan.

Merck & Co. key data

• Company: Merck & Co., Inc.
• ISIN: US58933Y1055
• Ticker: MRK
• Trading venue: NYSE
• Price (as of September 1, 2026, 16:28): 150.17 USD
• Market capitalization: 377,000,000,000 USD (as of September 1, 2026)
• Sector / Industry: Pharmaceuticals / Biotechnology
• Index membership: S&P 500